Agenus and Zydus sign agreements for botensilimab and balstilimab
Agenus has signed $141m partnership agreements with Zydus Lifesciences, expanding patient access to BOT/BAL.
Agenus has signed $141m partnership agreements with Zydus Lifesciences, expanding patient access to BOT/BAL.
What's Your Reaction?
